Trevi Therapeutics (NASDAQ:TRVI) Stock Price Up 7.9% – What’s Next?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) rose 7.9% on Friday . The company traded as high as $14.72 and last traded at $14.5250. Approximately 378,415 shares traded hands during mid-day trading, a decline of 73% from the average daily volume of 1,408,402 shares. The stock had previously closed at $13.46.

Wall Street Analyst Weigh In

TRVI has been the subject of a number of analyst reports. Oppenheimer restated an “outperform” rating on shares of Trevi Therapeutics in a report on Monday, March 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Monday, April 20th. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 target price on shares of Trevi Therapeutics in a research report on Wednesday, May 6th. D. Boral Capital reaffirmed a “buy” rating and issued a $19.00 target price on shares of Trevi Therapeutics in a research report on Friday, April 17th. Finally, Wall Street Zen lowered Trevi Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $22.90.

Trevi Therapeutics Trading Up 5.6%

The stock has a 50-day simple moving average of $13.96 and a 200-day simple moving average of $12.49. The company has a market capitalization of $2.02 billion, a price-to-earnings ratio of -44.41 and a beta of 1.04.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.02). On average, research analysts forecast that Trevi Therapeutics, Inc. will post -0.47 EPS for the current year.

Institutional Investors Weigh In On Trevi Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. KBC Group NV acquired a new stake in shares of Trevi Therapeutics during the 1st quarter valued at approximately $29,000. Hilton Head Capital Partners LLC acquired a new stake in shares of Trevi Therapeutics during the 4th quarter valued at approximately $40,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Trevi Therapeutics during the 4th quarter valued at approximately $50,000. Russell Investments Group Ltd. raised its position in shares of Trevi Therapeutics by 194.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock valued at $25,000 after acquiring an additional 2,996 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Trevi Therapeutics by 32.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,231 shares of the company’s stock valued at $78,000 after acquiring an additional 1,523 shares in the last quarter. 95.76% of the stock is owned by institutional investors and hedge funds.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.